Skip to main content
Abbott's molecular CMV test wins FDA approval
6/28/2017

The FDA has given Abbott approval for its RealTime CMV molecular test, a PCR-based assay designed to facilitate the management of hematopoietic stem cell transplant patients receiving cytomegalovirus treatment. The test, which is intended to be run on the company's m2000 RealTime platform, has the ability to amplify two select regions of the cytomegalovirus genome, reducing the risk of detection failure or underquantitation.

Full Story: